104 related articles for article (PubMed ID: 20729728)
21. 5q14.3 deletion neurocutaneous syndrome: Contiguous gene syndrome caused by simultaneous deletion of RASA1 and MEF2C: A progressive disease.
Ilari R; Agosta G; Bacino C
Am J Med Genet A; 2016 Mar; 170(3):688-93. PubMed ID: 26774077
[TBL] [Abstract][Full Text] [Related]
22. Assignment of human myocyte-specific enhancer binding factor 2C (hMEF2C) to human chromosome 5q14 and evidence that MEF2C is evolutionarily conserved.
Krainc D; Haas M; Ward DC; Lipton SA; Bruns G; Leifer D
Genomics; 1995 Oct; 29(3):809-11. PubMed ID: 8575784
[No Abstract] [Full Text] [Related]
23. Evolutionary genetic analyses of MEF2C gene: implications for learning and memory in Homo sapiens.
Kalmady SV; Venkatasubramanian G; Arasappa R; Rao NP
Asian J Psychiatr; 2013 Feb; 6(1):56-9. PubMed ID: 23380319
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity.
Kang J; Gocke CB; Yu H
BMC Biochem; 2006 Feb; 7():5. PubMed ID: 16478538
[TBL] [Abstract][Full Text] [Related]
25. MEF2C mutations are a rare cause of Rett or severe Rett-like encephalopathies.
Lambert L; Bienvenu T; Allou L; Valduga M; Echenne B; Diebold B; Mignot C; Héron D; Roth V; Saunier A; Moustaïne A; Jonveaux P; Philippe C
Clin Genet; 2012 Nov; 82(5):499-501. PubMed ID: 22449245
[No Abstract] [Full Text] [Related]
26. [Properties comparing and evolutionary analysis of MEF2 of Homo sapiens based on bioinformatic methods].
Guo XJ
Yi Chuan; 2011 Sep; 33(9):975-81. PubMed ID: 21951798
[TBL] [Abstract][Full Text] [Related]
27. Partial MEF2C deletion in a Cypriot patient with severe intellectual disability and a jugular fossa malformation: review of the literature.
Tanteles GA; Alexandrou A; Evangelidou P; Gavatha M; Anastasiadou V; Sismani C
Am J Med Genet A; 2015 Mar; 167A(3):664-9. PubMed ID: 25691421
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine phenotypes in a boy with 5q14 deletion syndrome implicate the regulatory roles of myocyte-specific enhancer factor 2C in the postnatal hypothalamus.
Sakai Y; Ohkubo K; Matsushita Y; Akamine S; Ishizaki Y; Torisu H; Ihara K; Sanefuji M; Kim MS; Lee KU; Shaw CA; Lim J; Nakabeppu Y; Hara T
Eur J Med Genet; 2013 Sep; 56(9):475-83. PubMed ID: 23832106
[TBL] [Abstract][Full Text] [Related]
29. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice.
Xu J; Gong NL; Bodi I; Aronow BJ; Backx PH; Molkentin JD
J Biol Chem; 2006 Apr; 281(14):9152-62. PubMed ID: 16469744
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity.
Zhu B; Gulick T
Mol Cell Biol; 2004 Sep; 24(18):8264-75. PubMed ID: 15340086
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C.
Sartorelli V; Huang J; Hamamori Y; Kedes L
Mol Cell Biol; 1997 Feb; 17(2):1010-26. PubMed ID: 9001254
[TBL] [Abstract][Full Text] [Related]
32. 5q14.3 Microdeletions: A Contiguous Gene Syndrome with Capillary Malformation-Arteriovenous Malformation Syndrome and Neurologic Findings.
Park SM; Kim JM; Kim GW; Kim HS; Kim BS; Kim MB; Ko HC
Pediatr Dermatol; 2017 Mar; 34(2):156-159. PubMed ID: 28297145
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
Agatheeswaran S; Singh S; Biswas S; Biswas G; Chandra Pattnayak N; Chakraborty S
Leukemia; 2013 Jul; 27(7):1578-80. PubMed ID: 23174904
[No Abstract] [Full Text] [Related]
34. MEF2C deletions and mutations versus duplications: a clinical comparison.
Novara F; Rizzo A; Bedini G; Girgenti V; Esposito S; Pantaleoni C; Ciccone R; Sciacca FL; Achille V; Della Mina E; Gana S; Zuffardi O; Estienne M
Eur J Med Genet; 2013 May; 56(5):260-5. PubMed ID: 23402836
[TBL] [Abstract][Full Text] [Related]
35. A novel 5q11.2 microdeletion in a child with mild developmental delay and dysmorphic features.
Fontana P; Tortora C; Petillo R; Falco M; Miniero M; De Brasi D; Pisanti MA
Am J Med Genet A; 2016 Sep; 170(9):2445-8. PubMed ID: 27374896
[TBL] [Abstract][Full Text] [Related]
36. mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo.
Dodou E; Xu SM; Black BL
Mech Dev; 2003 Sep; 120(9):1021-32. PubMed ID: 14550531
[TBL] [Abstract][Full Text] [Related]
37. Cooperation between MEF2 and PPARgamma in human intestinal beta,beta-carotene 15,15'-monooxygenase gene expression.
Gong X; Tsai SW; Yan B; Rubin LP
BMC Mol Biol; 2006 Feb; 7():7. PubMed ID: 16504037
[TBL] [Abstract][Full Text] [Related]
38. Exon 11 deletion in the myocyte enhancer factor (MEF)2A and early onset coronary artery disease gene in a Sicilian family.
Maiolino G; Colonna S; Zanchetta M; Pedon L; Seccia TM; Cesari M; Vigili de Kreutzenberg S; Avogaro A; Rossi GP
Eur J Cardiovasc Prev Rehabil; 2011 Aug; 18(4):557-60. PubMed ID: 21450604
[TBL] [Abstract][Full Text] [Related]
39. Transcription factor 4 and myocyte enhancer factor 2C mutations are not common causes of Rett syndrome.
Armani R; Archer H; Clarke A; Vasudevan P; Zweier C; Ho G; Williamson S; Cloosterman D; Yang N; Christodoulou J
Am J Med Genet A; 2012 Apr; 158A(4):713-9. PubMed ID: 22383159
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis of essential cardiac transcription factors in 256 patients with non-syndromic congenital heart defects.
Kodo K; Nishizawa T; Furutani M; Arai S; Ishihara K; Oda M; Makino S; Fukuda K; Takahashi T; Matsuoka R; Nakanishi T; Yamagishi H
Circ J; 2012; 76(7):1703-11. PubMed ID: 22498567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
